Comparison · NCT00476086-sae
Oxaliplatin/ Gemcitabine vs Radiation: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oxaliplatin/ Gemcitabine vs Radiation: serious adverse events. Trial comparisons, record NCT00476086-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00476086-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.105 | 0.0294 | 0.314 | wilson | |
| Risk in group 2 | 0.133 | 0.0374 | 0.379 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0281 | -0.285 | 0.202 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.789 | 0.125 | 4.97 | log | |
| Odds ratio, group 1 over group 2 | 0.765 | 0.0947 | 6.17 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Oxaliplatin/ Gemcitabine than on Radiation | 35.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oxaliplatin/ Gemcitabine | Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. | 2 | 19 | EG000 |
| Group 2 | Radiation | On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed. | 2 | 15 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Assessed each cycle of chemotherapy and week of radiation therapy from time of first dose and up to day 30 post-treatment. Participants received a median of 3 cycles (1 cycle = 4 weeks) of chemotherapy and 5 weeks of radiation therapy.
Source ClinicalTrials.gov
Trial
- Title
- Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
- NCT number
- NCT00476086
- Phases
- PHASE2
- Conditions
- Mixed Mullerian Tumors of the Uterus
- Interventions
- Gemcitabine, Oxaliplatin, Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2016-04-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00476086?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00476086-sae